| gap-pubmed-20260411- | What are the specific molecular mechanisms by which JAK1/2 inhibition reverses H | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Does TE mobilization occur in other neurodegenerative diseases through similar c | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does c-Jun specifically target heterochromatic TE regions for decondensation | open | 0.80 | 0.00 | 2026-04-11 | 0 | | epigenetics |
| gap-pubmed-20260411- | What upstream mechanisms trigger c-Jun upregulation specifically in Alzheimer's | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can diagnostic heterogeneity and symptom overlap with other dementias be mec | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms underlie the convergence of multifactorial AD pathways into unif | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do many amyloid and tau-targeting therapeutics fail despite clear pathologic | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does PI3K/AKT pathway disruption specifically lead to neurogenesis inhibitio | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurogenesis |
| gap-pubmed-20260411- | What mechanisms mediate the gut-brain axis communication in nanoplastic-induced | open | 0.74 | 0.00 | 2026-04-11 | 0 | | gut-brain-axis |
| gap-pubmed-20260411- | Why do nanoplastics cause neuron loss while microplastics cause dendritic spine | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurotoxicology |
| gap-pubmed-20260411- | Why does HDAC3 specifically promote ferroptosis in oligodendrocytes versus other | open | 0.74 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What drives the initial iron deposition in white matter injury that triggers the | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does the HDAC3-PDK4 axis mechanistically regulate iron homeostasis and ferro | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do aldehyde-mediated and oxyradical-mediated modifications synergistically d | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What makes certain neuronal populations vulnerable to 90% loss while others are | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do lipid peroxidation and advanced glycation pathways interact to produce CM | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do only 3-4% of MSP1 patients develop parkinsonism despite carrying the same | open | 0.74 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms link VCP mutations to alpha-synuclein aggregation in M | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the distinct molecular triggers that initiate cuproptosis in different | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do organ-specific mechanisms regulate cuproptosis differently in the CNS ver | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines cell-type-specific manifestations of cuproptosis pathways in dif | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Which specific structural forms of α-synuclein amyloid assemblies are most toxic | open | 0.84 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific molecular mechanisms by which α-synuclein amyloid assembli | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Does oligodendroglia dysfunction contribute causally to PD pathogenesis or repre | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do heat shock protein overexpression and immune responses interact in PD oli | open | 0.74 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What molecular mechanisms drive oligodendrocyte transition from mature to diseas | resolved | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why did intrathecal mesenchymal stem cell therapy fail to meet efficacy endpoint | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What biomarkers can definitively diagnose ALS and track disease progression? | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do current ALS therapies show modest benefits but cannot halt or reverse dis | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does chronic stress mechanistically modulate microglial-mediated synaptic re | open | 0.82 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What determines whether microglia adopt beneficial vs. harmful phenotypes in chr | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Why does group VII phospholipase A2 increase while types IVA and VIA are specifi | open | 0.73 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What mechanisms drive SREBP-1c-independent upregulation of delta-6 desaturase an | open | 0.77 | 0.00 | 2026-04-11 | 0 | | metabolic-neurodegeneration |
| gap-pubmed-20260411- | How does cholesterol excess trigger proportional ApoE upregulation during neurod | open | 0.72 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do plasma and CSF 24OHC levels show opposite changes in neurodegeneration de | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms explain how 27OHC antagonizes 24OHC's protective effec | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can glymphatic imaging biomarkers be validated for diagnostic use in neurode | open | 0.86 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What specific mechanisms link glymphatic dysfunction to aging and neurodegenerat | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do different glymphatic clearance routes (BBB efflux, IPAD, meningeal lympha | resolved | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do women and men show different plasma-to-brain tau relationships despite si | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Should sex-specific cutoff values be established for plasma p-tau181 in clinical | open | 0.84 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What biological mechanisms cause plasma p-tau181 to have stronger associations w | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms drive the synthetic lethality between SETX deficiency | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does BIR preferentially activate at double-ended DSBs when its canonical rol | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines whether ubiquitination leads to proteolysis versus functional sw | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do different stress types modulate ubiquitin system components and machinery | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does age versus neuropathology differentially determine COVID-19 vulnerabili | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroimmunology |
| gap-pubmed-20260411- | How does SARS-CoV-2 infection lead to future neurodegeneration as a long-term co | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms explain how COVID-19 infection modifies the clinical spectrum of | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How do different G-protein coupling pathways (Gq vs Go/G12) coordinate P2Y2R cel | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |